BioSpace News Archive

Blueprint Medicines Corporation announced that, effective on January 1, 2022, the Compensation Committee of Blueprint Medicines’ Board of Directors granted non-qualified stock options to purchase an aggregate of 9,725 shares of its common stock and an aggregate of 4,862 restricted stock units to seven new employees under Blueprint Medicines’ 2020 Inducement Plan.

Dynacure, a clinical stage biotechnology company focusing on Myotubular and Centronuclear Myopathies (CNM), a group of rare, debilitating, and life-threatening genetic diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for its lead product candidate, DYN101.

Simulations Plus, Inc., a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, reported financial results for its first quarter of fiscal 2022, ended November 30, 2021.

CooperCompanies, will present at the J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022.

Immuneering Corporation (Nasdaq: IMRX), a biopharmaceutical company advancing a robust pipeline of oncology and neuroscience product candidates that are designed to uniquely disrupt cellular signaling dynamics, today announced preclinical data highlighting the potential of its lead product candidate, IMM-1-104, to inhibit tumor growth in NRAS mutant melanoma models.

Tiziana Life Sciences, a biotechnology company enabling breakthrough immunotherapies via novel routes of drug delivery, announced that senior management will present at the Biotech Showcase Conference and be available for one-on-one meetings throughout the conference.

Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that Bryan Stuart, President and Chief Executive Officer, will present at the virtual 40th Annual J.P. Morgan Healthcare Conference on Thursday, January 13, 2022 at 12:00 p.m. ET.

Acepodia, a clinical-stage biotechnology company developing first-in-class cell therapies with its unique Antibody-Cell Conjugation platform technology to address gaps in cancer care, announced it has appointed David V. Smith to its Board of Directors and Elizabeth Smith and Richard Lopez, M.D., to its Scientific Advisory Board.

I-Mab, a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, announced that the senior management team of the Company

Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that it has halted further development of its STOPS™ drug candidate, ALG-010133, in development to address chronic hepatitis B (CHB).